Latest filings (excl ownership)
15-12G
Securities registration termination
5 Sep 23
S-8 POS
Registration of securities for employees (post-effective amendment)
23 Aug 23
8-K
Completion of Acquisition or Disposition of Assets
23 Aug 23
25-NSE
Exchange delisting
23 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
22 Aug 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
18 Aug 23
DEFA14A
Additional proxy soliciting materials
16 Aug 23
8-K
Other Events
15 Aug 23
425
Business combination disclosure
11 Aug 23
425
Business combination disclosure
11 Aug 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
425
Business combination disclosure
30 Jun 23
DEFM14A
Proxy related to merger
30 Jun 23
425
Business combination disclosure
25 May 23
425
Business combination disclosure
24 May 23
425
Business combination disclosure
24 May 23
425
Business combination disclosure
24 May 23
8-K
Pyxis Oncology to Acquire Apexigen
24 May 23
10-Q
2023 Q1
Quarterly report
15 May 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
12 Apr 23
424B3
Prospectus supplement
10 Apr 23
424B3
Prospectus supplement
10 Apr 23
EFFECT
Notice of effectiveness
10 Apr 23
EFFECT
Notice of effectiveness
10 Apr 23
POS AM
Prospectus update (post-effective amendment)
4 Apr 23
POS AM
Prospectus update (post-effective amendment)
4 Apr 23
EFFECT
Notice of effectiveness
22 Mar 23
424B3
Prospectus supplement
21 Mar 23
CORRESP
Correspondence with SEC
20 Mar 23
S-1/A
IPO registration (amended)
17 Mar 23
8-K
Apexigen Announces Review of Strategic Alternatives and Restructuring
27 Feb 23
S-1
IPO registration
22 Feb 23
10-K
2022 FY
Annual report
22 Feb 23
8-K
Departure of Directors or Certain Officers
14 Feb 23
D
$5.59 mm in equity / options / securities to be acquired, sold $5.59 mm, 13 investors
13 Feb 23
8-K
Unregistered Sales of Equity Securities
1 Feb 23
424B3
Prospectus supplement
30 Jan 23
424B3
Prospectus supplement
30 Jan 23
8-K
Apexigen Announces Approximately $2.8 Million
25 Jan 23
10-Q
2022 Q3
Quarterly report
14 Nov 22
Latest ownership filings
4
Dan Zabrowksi
25 Aug 23
4
Samuel P Wertheimer
25 Aug 23
4
Scott Andrew Smith
25 Aug 23
4
GORDON RINGOLD
25 Aug 23
4
Meenu Chhabra
25 Aug 23
4
Jakob Dupont
25 Aug 23
4
HERB CROSS
25 Aug 23
4
Amy Wong
25 Aug 23
4
Francis Willard Sarena
25 Aug 23
4
Frank J. Hsu
25 Aug 23
4
William E. Duke
25 Aug 23
4
Xiaodong Yang
25 Aug 23
3/A
Jakob Dupont
24 Aug 23
4
Xiaodong Yang
23 Jun 23
4
Amy Wong
23 Jun 23
4
Francis Willard Sarena
23 Jun 23
4
Frank J. Hsu
23 Jun 23
4
William E. Duke
23 Jun 23
4
Amy Wong
25 May 23
4
William E. Duke
25 May 23
4
Francis Willard Sarena
25 May 23
4
Samuel P Wertheimer
23 May 23
SC 13G/A
PERISCOPE CAPITAL INC.
13 Feb 23
SC 13G
Yang Xiaodong
13 Feb 23
SC 13G/A
Kepos Capital LP
26 Jan 23
4
Amy Wong
19 Dec 22
4
Francis Willard Sarena
19 Dec 22
4
Frank J. Hsu
19 Dec 22
4
William E. Duke
19 Dec 22
4
Xiaodong Yang
19 Dec 22
4
Amy Wong
11 Oct 22
4
Francis Willard Sarena
11 Oct 22
4
Frank J. Hsu
11 Oct 22
4
William E. Duke
11 Oct 22
4
Xiaodong Yang
11 Oct 22
4
Dan Zabrowksi
3 Oct 22
4
Samuel P Wertheimer
3 Oct 22
4
Scott Andrew Smith
3 Oct 22
4
GORDON RINGOLD
3 Oct 22
4
Meenu Chhabra
3 Oct 22